One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists
暂无分享,去创建一个
Timo Krotzky | Gerhard Klebe | Nedyalka Radeva | Alexander Metz | Wibke E Diederich | Jean-Paul Renaud | Lars Neumann | G. Klebe | A. Heine | Timo Krotzky | A. Metz | M. Zeeb | J. Renaud | D. Roecklin | V. Vivat-Hannah | L. Neumann | Nina Schlinck | C. Atmanène | Andreas Heine | H. Köster | J. Schiebel | Dominique Roecklin | Markus Zeeb | Johannes Schiebel | Helene Köster | W. Diederich | M. Kuhnert | Robert Meinecke | R. Meinecke | Maren Kuhnert | Cedric Atmanene | Valérie Vivat-Hannah | Nina Schlinck | Astrid Sitte | Franziska Popp | Franziska Popp | N. Radeva | Astrid Sitte | Wibke E. Diederich | Cédric Atmanène
[1] Tom Blundell,et al. The active site of aspartic proteinases , 1991, FEBS letters.
[2] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[3] Dieter Braun,et al. Molecular interaction studies using microscale thermophoresis. , 2011, Assay and drug development technologies.
[4] D. Scott,et al. Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.
[5] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[6] Claudio Dalvit,et al. Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. , 2003, Journal of the American Chemical Society.
[7] Jonathan Bard,et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.
[8] Olan Dolezal,et al. Parallel Screening of Low Molecular Weight Fragment Libraries , 2013, Journal of biomolecular screening.
[9] G. Klebe,et al. Thermodynamic signatures of fragment binding: Validation of direct versus displacement ITC titrations. , 2015, Biochimica et biophysica acta.
[10] Gerhard Müller,et al. Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology , 2009, J. Comput. Aided Mol. Des..
[11] B. Ganem,et al. Detection of noncovalent receptor-ligand complexes by mass spectrometry , 1991 .
[12] A. Dorsselaer,et al. Nondenaturing mass spectrometry to study noncovalent protein/protein and protein/ligand complexes: technical aspects and application to the determination of binding stoichiometries. , 2008, Methods in molecular biology.
[13] Glyn Williams,et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.
[14] Gerhard Klebe,et al. Tracing binding modes in hit-to-lead optimization: chameleon-like poses of aspartic protease inhibitors. , 2015, Angewandte Chemie.
[15] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[16] Andrew L Hopkins,et al. Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.
[17] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[18] C. Abell,et al. A fragment-based approach to identifying ligands for riboswitches. , 2010, ACS chemical biology.
[19] T Neumann,et al. SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.
[20] Kristin A. Sannes-Lowery,et al. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes , 2006, Nature Reviews Drug Discovery.
[21] J. Whitaker,et al. Endothia parasitica Protease. Parameters Affecting Stability of the Rennin-like Enzyme , 1970 .
[22] Chris Abell,et al. A three-stage biophysical screening cascade for fragment-based drug discovery , 2013, Nature Protocols.
[23] Florian Pröll,et al. Direct optical detection in fragment-based screening , 2009, Analytical and bioanalytical chemistry.
[24] K Gubernator,et al. Design and synthesis of potent and highly selective thrombin inhibitors. , 1994, Journal of medicinal chemistry.
[25] D. Ringe,et al. Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.
[26] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[27] Bernd Meyer,et al. Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.
[28] C. Schalk-Hihi,et al. Protein thermal shifts to identify low molecular weight fragments. , 2011, Methods in enzymology.
[29] Gerhard Klebe,et al. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.
[30] G. Klebe,et al. Experimental and Computational Active Site Mapping as a Starting Point to Fragment‐Based Lead Discovery , 2012, ChemMedChem.
[31] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[32] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[33] P. Śledź,et al. High-Throughput Interrogation of Ligand Binding Mode Using a Fluorescence-Based Assay** , 2012, Angewandte Chemie.
[34] B. Meyer,et al. Charakterisierung von Ligandenbindung durch Sättigungstransfer‐Differenz‐NMR‐Spektroskopie , 1999 .
[35] G. Fogliatto,et al. WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.
[36] D. Braun,et al. Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. , 2013, Methods.
[37] Jan Schultz,et al. Integration of fragment screening and library design. , 2007, Drug discovery today.
[38] Victor S. Lobanov,et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .
[39] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[40] Wolfgang Jahnke,et al. Fragment-based Approaches in Drug Discovery: JAHNKE: FRAGMENT-BASED APPROACHES IN DRUG DISCOVERY O-BK , 2006 .
[41] D. Ullmann,et al. HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature. , 2011, Methods in enzymology.
[42] Wolfgang Jahnke and Daniel A. Erlanson. Fragment-based approaches in drug discovery , 2013 .
[43] T. O'Brien,et al. Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.
[44] H Roos,et al. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. , 2000, Journal of medicinal chemistry.
[45] G. Klebe,et al. Chamäleon‐artige Bindungsmodi in der Leitstrukturoptimierung: wechselnde Bindungsgeometrien bei Aspartylprotease‐Inhibitoren , 2015 .
[46] Chris Abell,et al. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery , 2013, Proceedings of the National Academy of Sciences.
[47] Claudio Dalvit,et al. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. , 2009, Drug discovery today.
[48] A. van Dorsselaer,et al. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery. , 2010, Future medicinal chemistry.